Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arikayce extension in CF with Pseudomonas aeruginosa
NCT03905642Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Jan 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of amikacin in Pseudomonas aeruginosa infection, sponsored by Insmed Incorporated. Primary endpoint: Adverse Event Profile of 560 mg Once Daily Dose of Arikayce™ Administered for Six Cycles Over Eighteen Months at 18 Months. Started Jan 2009; status: completed.
02
Drugs
amikacin
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT03905642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905642.